ArticleTranslational cancer research2025
Immunogenomic classification and nomogram development and validation for colorectal cancer survival prediction based on immune-related genes.
Article in Translational cancer research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Colorectal cancer (CRC) is the third most common digestive cancer, and immunity plays an important role in the development of CRC. In this study, we aimed to explore immune-related prognostic biomarkers. Methods: We first explored the immune microenvironment and identified a high immune score cluster and a low immune score cluster on the basis of the immune score calculated by single-sample gene set enrichment analysis (ssGSEA). We also explored the differentially expressed genes (DEGs) between the high- and low-immune score groups and utilized weighted gene coexpression network analysis (WGCNA) to explore the gene sets with the highest correlation with prognosis. DEGs between paracancerous and tumor tissues were discovered on the basis of the RNA sequencing results, and immune-related differentially expressed genes (IRDEGs) were obtained by the intersection of the DEGs with the prognosis-related gene sets determined by WGCNA. Least absolute shrinkage and selection operator (LASSO) regression and multivariate Cox regression (multi Cox) were used to screen risk factors for overall survival in CRC patients, and a risk score model and nomogram were constructed. We also assessed the relationships among immune infiltration, cancer transcription factor targets and risk factors in the prognostic model. Results: Based on the immune enrichment, we divided CRC patients into high and low immune score groups, and the low-immune score group had a better survival rate. The brown cluster of WGCNA is associated with prognosis, the hub DEGs between the brown cluster and RNA sequencing, and we explore the 26 genes. Based on hub DEGs, we developed and validated a risk score model, areas under the curve (AUCs) of 1-, 3-, and 5-year survival were 0.75,0.73, and 0.65, indicating good accuracy and the low-risk score group had a better prognosis(P<0.0001). Combined risk score and clinical information, the nomogram also has good prediction value, the AUC for 1-year survival was 0.809, that for 3-year survival was 0.804, and that for 5-year survival was 0.794. Conclusions: Immunogenomic classification can identify different immune statuses of CRC patients and predict survival.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.